French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
کمپنیوں نے بدھ کے روز کہا کہ وہ ویکسین کے آخری مرحلے کے ٹرائل سے ریگولیٹرز کو ڈیٹا جمع کرنے کا ارادہ رکھتے ہیں، اور ایک اور اس کی جانچ بوسٹر کے طور پر کر رہے ہیں، دونوں مطالعات کے مکمل نتائج کے ساتھ "اس سال کے آخر میں" شائع ہونے کی امید ہے۔
سنوفی COVID-19 شاٹس کی دوڑ میں پیچھے پڑنے کے بعد واپسی کی امید کر رہا ہے، جب کہ فروخت کے لحاظ سے دنیا کی سب سے بڑی ویکسین بنانے والی کمپنی GSK نے اپنا امیدوار تیار نہیں کیا ہے اور اس کے بجائے وہ ڈویلپرز کو اپنی معاون ٹیکنالوجی فراہم کر رہا ہے۔
The two businesses have partnered to produce a pandemic adjuvant from GSK and a recombinant antigen from Sanofi. Both companies have built vaccination platforms that have demonstrated efficacy against influenza.
Our state-of-the-art, global healthcare organization is committed to improving people’s lives by utilizing the miracles of science. Our team, which is dispersed over nearly 100 countries, is dedicated to making the seemingly impossible feasible in an effort to transform the medical field. We provide potentially life-saving medical treatments and vaccine protection to millions of people globally, all while keeping sustainability and social responsibility at the center of our mission. Sanofi is traded on EURONEXT: SAN and NASDAQ: SNY.
GSK cautions investors that there are risks and uncertainties that might cause actual results to differ materially from those anticipated when relying on any forward-looking statements or predictions made by the business, including the ones included in this communication. Some of these variables are listed in the Company’s 2020 Annual Report on Form 20-F, the Q4 results from GSK in 2021, and any COVID-19 pandemic effects, but they are not the only ones.
Also Read: کوویڈ 19 مثبت ملک میں 2.84 فیصد کمی
